MKI67 and breast carcinoma: Difficulties in reproducing the Ki-67 labelling index are particularly crucial in the intermediate range proliferative luminal B-like breast cancers, as published data are reaching a consensus on this delicate issue and advising caution with the use of this biomarker4,5,8,11,18–20,22–28.